Sunday, August 11, 2013
Pavilion (Sheraton San Diego)
Lactobacillus JB9489 is a probiotic strain that showed strong anti-obesity effect in animal experiments. The strain is currently under clinical trial at Samsung Hospital (Seoul, Korea). This study seeks to develop a low cost industrial medium for maximum production of Lactobacillus sp. JB9489 for use as a starter for anti-obesity dairy products. Trials were done on mice to investigate the health effects of the probiotic on animals. The one factor at a time (OFAT), Plackett–Burman design (PBD), Fractional factorial design (FFD), steepest ascent method (SAM) and response surface method (RSM) were used. Animal experiments results are as follows: JBD3012 had the greatest positive effect on weight gain followed by JBD3011, L. acidophilus and the control; JBD3012 tests on the lipid profile resulted in the least concentration of lipids (TG, TC, LDL) compared to the control, L. acidophilus, JBD3011; it resulted in maintenance of glucose concentrations; comparison of our probiotic with orlistat indicated that just like orlistat it reduces the weight of obese mice by 11.7 %; and the probiotic reduced subcutaneous and abdominal fat by 15% and did not show side effects. OFAT identified sucrose, skim milk, yeast extract, K2HPO4, sodium citrate dihydrate, MgSO4 as key components. PBD identified skim milk, yeast extract and sodium citrate dehydrate as critical factors in biomass production. The optimum medium composition was established to be (g/L); sucrose 20, skim milk 66.32, yeast extract 59.11, K2HPO4 2.0, sodium citrate dihydrate 7.86 and MgSO4 2.0 yielding a maximum biomass of 14.46 g/L.